Actinogen Medical (ASX:ACW) has hit a significant milestone in its push to bring a new oral Alzheimer’s therapy to market, completing enrolment in its pivotal XanaMIA trial and confirming November 2026 for topline results.
Actinogen crosses key milestone as pivotal Alzheimer’s trial fully enrols
December 18, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Episode 1, Series 5
January 23, 2026 - - Podcast -
AusBiotech announces new advisory groups to support the life sciences sector
January 22, 2026 - - Latest News -
Specialised Therapeutics brings new hope to women with HER2-positive breast cancer in Thailand
January 22, 2026 - - Latest News -
New funding deal brings next-generation cystic fibrosis treatments closer for New Zealanders
January 22, 2026 - - Latest News -
For almost all of the last 40 years, Governments have aimed to make medicines less affordable, for everyone but them
January 22, 2026 - - Latest News -
argenx deepens Australian research footprint with Monash partnership
January 21, 2026 - - Latest News -
New data reinforce promise of cancer vaccine, with Australia playing a key role
January 21, 2026 - - Latest News

